Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Aldurazyme Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
Historical expansion was driven by the scarcity of treatment options for MPS I, the severe health complications arising from untreated GAG accumulation, progress in recombinant enzyme technology, enhanced diagnostics for rare diseases, and the development of orphan drug frameworks.
Projected growth within the forecast period is fueled by the expansion of newborn screening initiatives, a surge in investments for rare disease therapies, enhanced patient survival rates, the development of specialized care infrastructure, and improved reimbursement provisions for orphan drugs.
Dominant trends anticipated during the forecast period involve the increasing adoption of enzyme replacement therapies, a heightened focus on rare genetic disorders, the broadening of programs for early diagnosis and treatment, more extensive long-term management of MPS I, and the reinforcement of specialized treatment centers.
Get A Free Sample Report With In-Depth Market Insights:
Aldurazyme Market Development Factors: What’s Supporting Demand?
The aldurazyme market is expected to grow, driven by an increasing number of clinical trials. These research studies are conducted with human participants to evaluate the safety, efficacy, and potential side effects of novel treatments, drugs, or medical devices. The rise in clinical trials is attributed to the escalating demand for innovative therapies, advancements in medical research, and a greater emphasis on personalized healthcare. Such trials positively impact aldurazyme by yielding vital data on its safety, effectiveness, and long-term benefits for individuals with mucopolysaccharidosis type I, thereby aiding in the refinement of treatment protocols and the expansion of its clinical usage. For instance, in February 2024, ClinicalTrials.gov, a US-based government web resource, indicated that clinical trial result publications increased from 4,024 in 2022 to 5,063 in 2023. Consequently, the growing volume of clinical trials is a key factor propelling the expansion of the aldurazyme market.
Aldurazyme Market Segment Outlook: Which Categories Are Growing Fastest?
The aldurazyme market covered in this report is segmented –
1) By Indication: Hurler Syndrome, Hurler-Scheie, Scheie
2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies
3) By End User: Pediatric, Adult, Geriatric
Aldurazyme Market Leading Companies And Competitive Benchmarking
Major companies operating in the aldurazyme market are BioMarin Pharmaceuticals Inc., Sanofi S.A.
View The Full Aldurazyme Market Report:
Aldurazyme Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the aldurazyme market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aldurazyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Leave a Reply